For example, personalized vaccines composed of an individual patient’s tumor neoantigens might be taken up and presented by activated APCs, leading to the activation of specific T cells that target these neoantigens, and thereby enhancing the efficacy of PD-1/PD-L1 inhibitors (311). Here, PDCD1 is linked to neoplasm.